Madeleine Williams
Stock Analyst at Canaccord Genuity
(0.11)
# 4,263
Out of 4,339 analysts
73
Total ratings
31.6%
Success rate
-19.4%
Average return
Main Sectors:
Stocks Rated by Madeleine Williams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: CU6 Clarity Pharmaceuticals Ltd | Maintained: Buy | $8.41 | $2.65 | +217.36% | 11 | May 26, 2026 | |
| ASX: SNT Syntara Limited | Maintained: Buy | $0.15 | $0.026 | +476.92% | 8 | May 23, 2026 | |
| ASX: EBR EBR Systems, Inc. | Maintained: Buy | $2.43 | $0.445 | +446.07% | 11 | May 20, 2026 | |
| ASX: NEU Neuren Pharmaceuticals Limited | Maintained: Buy | $24.00 | $14.44 | +66.20% | 5 | May 19, 2026 | |
| ASX: IMR Imricor Medical Systems, Inc. | Rated: Buy | $2.33 → $2.28 | $1.77 | +28.81% | 6 | May 19, 2026 | |
| ASX: PME Pro Medicus Limited | Maintained: Buy | $180.82 → $168.62 | $131.03 | +28.69% | 3 | May 12, 2026 | |
| ASX: M7T Mach7 Technologies Limited | Downgraded: Hold | $0.80 → $0.27 | $0.31 | -12.90% | 2 | May 12, 2026 | |
| ASX: BOT Botanix Pharmaceuticals Limited | Maintained: Buy | $0.14 | $0.024 | +483.33% | 5 | May 3, 2026 | |
| ASX: ATH Alterity Therapeutics Limited | Maintained: Buy | $0.01 | $0.009 | +11.11% | 3 | Apr 29, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Maintained: Buy | $2.85 → $2.84 | $1.40 | +103.29% | 2 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.23 | $2.11 | +53.08% | 4 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.15 | $2.61 | +20.69% | 4 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1.27 → $0.40 | $0.058 | +589.66% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32.84 → $27.90 | $8.90 | +213.66% | 2 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6.10 | $2.36 | +158.47% | 2 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27.33 → $27.41 | $13.73 | +99.71% | 2 | Oct 15, 2025 |
Clarity Pharmaceuticals Ltd
May 26, 2026
Maintained: Buy
Price Target: $8.41
Current: $2.65
Upside: +217.36%
Syntara Limited
May 23, 2026
Maintained: Buy
Price Target: $0.15
Current: $0.026
Upside: +476.92%
EBR Systems, Inc.
May 20, 2026
Maintained: Buy
Price Target: $2.43
Current: $0.445
Upside: +446.07%
Neuren Pharmaceuticals Limited
May 19, 2026
Maintained: Buy
Price Target: $24.00
Current: $14.44
Upside: +66.20%
Imricor Medical Systems, Inc.
May 19, 2026
Rated: Buy
Price Target: $2.33 → $2.28
Current: $1.77
Upside: +28.81%
Pro Medicus Limited
May 12, 2026
Maintained: Buy
Price Target: $180.82 → $168.62
Current: $131.03
Upside: +28.69%
Mach7 Technologies Limited
May 12, 2026
Downgraded: Hold
Price Target: $0.80 → $0.27
Current: $0.31
Upside: -12.90%
Botanix Pharmaceuticals Limited
May 3, 2026
Maintained: Buy
Price Target: $0.14
Current: $0.024
Upside: +483.33%
Alterity Therapeutics Limited
Apr 29, 2026
Maintained: Buy
Price Target: $0.01
Current: $0.009
Upside: +11.11%
PYC Therapeutics Limited
Apr 15, 2026
Maintained: Buy
Price Target: $2.85 → $2.84
Current: $1.40
Upside: +103.29%
Apr 14, 2026
Maintained: Buy
Price Target: $3.23
Current: $2.11
Upside: +53.08%
Apr 8, 2026
Maintained: Buy
Price Target: $3.15
Current: $2.61
Upside: +20.69%
Mar 13, 2026
Maintained: Buy
Price Target: $1.27 → $0.40
Current: $0.058
Upside: +589.66%
Mar 2, 2026
Maintained: Buy
Price Target: $32.84 → $27.90
Current: $8.90
Upside: +213.66%
Dec 22, 2025
Maintained: Buy
Price Target: $6.10
Current: $2.36
Upside: +158.47%
Oct 15, 2025
Maintained: Buy
Price Target: $27.33 → $27.41
Current: $13.73
Upside: +99.71%